* IRadimed Corp IRMD.OQ IRMD.O is expected to show a
rise in
quarterly revenue when it reports results on February 2.
* The Winter Springs Florida-based company is expected to
report
a 25.2% increase in revenue to $14.869 million from $11.87
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for IRadimed Corp is
for
earnings of 30 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for IRadimed
Corp is
$45.5, above its last closing price of $36.70.
This summary was machine generated January 31 at 19:31 GMT. All
figures in US dollars unless otherwise stated